Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Fiche publication
Date publication
avril 2021
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel, Pr NERICH Virginie, Dr THIERY-VUILLEMIN Antoine, Pr KLEINCLAUSS François
Tous les auteurs :
Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, Hennequin C, Morgans AK, Geoffrois L, Limat S, Thiery-Vuillemin A, Nerich V
Lien Pubmed
Résumé
The optimal therapeutic strategies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer (mCRPC), in terms of cost and effectiveness, remains unknown. This study aims to compare the cost-effectiveness of various potential strategies, from the start of first-line treatment in mHSPC to the death of the patients.
Mots clés
Castrate-resistant, Hormone-sensitive, Metastatic, Prostate cancer, cost-effectiveness analysis
Référence
Clin Genitourin Cancer. 2021 Apr 5;: